Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Active Treatment- CT1812 · 1 trial · 1 indication
Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.
| Arm | Type | Description |
|---|---|---|
| 300 mg | ACTIVE_COMPARATOR | High Dose CT1812 |
| 100 mg | ACTIVE_COMPARATOR | Low Dose CT1812 |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| Active Treatment- CT1812 100 mg | DRUG | CT1812 |
| Active Treatment- CT1812 300 mg | DRUG | CT1812 |
| Placebo | DRUG | Matching Placebo |
Inclusion Criteria: * Participants may be included in the study only if they meet all of the following criteria: 1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at ...
Top 20 of 24 competitors